Investigational drug · Phase 2
4D-310
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fabry Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "4D-310"
First trial start
2020
Sep 1, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "4D-310", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fabry Disease
Approved drugs for the same conditions: Fabry disease · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "4D-310" as an intervention, largest first.
4D Molecular TherapeuticsIndustry
NCT05629559 · 18 participants (planned) · Start Oct 16, 2022 · Primary completion Jun 2026
Drug: 4D-310 · For: Fabry Disease
Sites: Melbourne, Australia; Perth, Australia; Westmead, Australia · 4 sites in all
- An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry DiseaseActive, not recruiting
4D Molecular TherapeuticsIndustry
NCT04519749 · 18 participants (planned) · Start Sep 1, 2020 · Primary completion Jan 2026
Drug: 4D-310 · For: Fabry Disease
Sites: La Jolla, California; Atlanta, Georgia; Pittsburgh, Pennsylvania · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Fabry Disease
- VenglustatGZ402671Phase 35 trials
Sanofi · Fabry Disease, Gaucher's Disease Type III, Gaucher Disease Type 1
- LucerastatPhase 32 trials
Idorsia Pharmaceuticals Ltd. · Fabry Disease
- AMT-191Phase 21 trial
UniQure Biopharma B.V. · Fabry Disease
- EXG110Phase 21 trial
Guangzhou Jiayin Biotech Ltd · Fabry Disease
- ST-920Phase 21 trial
Sangamo Therapeutics · Fabry Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.